Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SEHK:6990 Rapporto sulle azioni
Cap. di mercato: HK$39.0b
Aggiungi alla lista di controlloSichuan Kelun-Biotech Biopharmaceutical Dividendi e riacquisti
Dividendo criteri di controllo 0/6 Sichuan Kelun-Biotech Biopharmaceutical non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
-5.1%
Rendimento del riacquisto
Rendimento totale per gli azionisti -5.1% Rendimento futuro dei dividendi 0% Crescita dei dividendi n/a Prossima data di pagamento dei dividendi n/a Data di stacco del dividendo n/a Dividendo per azione n/a Rapporto di remunerazione n/a
Aggiornamenti recenti su dividendi e riacquisti
Mostra tutti gli aggiornamenti
Price target increased by 7.4% to HK$215 Oct 22
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Multiple Clinical Research Results and Progress of TROP2-ADC Sacituzumab Tirumotecan at 2024 CSCO Annual Meeting Oct 01
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results from Core Product Sacituzumab Tirumotecan (Sac-Tmt) At 2024 Esmo Congress
Consensus revenue estimates increase by 48% Aug 26
First half 2024 earnings: EPS and revenues exceed analyst expectations Aug 23
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates Aug 21
New major risk - Revenue and earnings growth Aug 21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product Sacituzumab Tirumotecan (Sac-Tmt) Accepted by the National Medical Products Administration Aug 19
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 19, 2024 Aug 07
New minor risk - Share price stability Aug 03
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives Clinical Trial Notice Approving the Investigational New Drug Application for the Innovative Drug SKB518 Jun 18
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth Jun 14 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Board and Committee Changes Jun 01
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting May 25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024 May 23
Consensus EPS estimates fall by 41% Apr 01
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results Mar 27
New minor risk - Profitability Mar 27
No longer forecast to breakeven Mar 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 26
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 25, 2024 Mar 14
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 (EP0031) Granted Fast Track Designation by the US Food and Drug Administration Mar 12
New minor risk - Profitability Mar 07
New major risk - Revenue and earnings growth Mar 05
New minor risk - Share price stability Feb 14
An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued Jan 11
Forecast to breakeven in 2026 Dec 31
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration Dec 11
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product Nov 30
Consensus EPS estimates upgraded to CN¥1.73 loss Oct 21
Consensus EPS estimates upgraded to CN¥1.73 loss Oct 18
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Abstract for Oral Presentation of the Study Results from Core Product SKB264 (MK-2870) Published on the Website of the 2023 ESMO Congress Oct 17
Consensus estimates of losses per share improve by 11% Sep 05
First half 2023 earnings released Sep 01
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 18
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Phase III Clinical Trial of Core Product SKB264 (MK-2870) in Patients with Unresectable Local Advanced, Recurrent or Metastatic Triple-Negative Breast Cancer Aug 15
New major risk - Revenue and earnings growth Aug 04
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has completed an IPO in the amount of HKD 1.360234 billion. Jul 11
Less than half of directors are independent Jul 11
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di 6990 siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di 6990 siano aumentati.
Rendimento dei dividendi rispetto al mercato Sichuan Kelun-Biotech Biopharmaceutical Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di 6990 rispetto al mercato? Segmento Rendimento dei dividendi Azienda (6990) n/a Fondo del 25% del mercato (HK) 3.1% Top 25% del mercato (HK) 7.9% Media del settore (Biotechs) 1.0% Analista previsionale (6990) (fino a 3 anni) 0%
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di 6990 rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di 6990 rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di 6990 per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché 6990 non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}